findnerd.com

jQuery .prop() vs .attr()

Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...
FiercePharma

Pfizer reported an ATTR sales decline in the US. Should newer market entrants Alnylam and BridgeBio worry?

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...
Health.com

4 Ways Doctors Can Detect ATTR-CM, a Rare and Difficult-To-Diagnose Heart Condition

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
PharmaTimes

NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...
Medscape

NICE Endorses Vutrisiran for ATTR-CM Treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
rarediseaseadvisor

Coramitug May Slow Disease Progression in ATTR-CM

Coramitug is well tolerated and leads to a statistically significant reduction in N-terminal pro-brain type natriuretic peptide (NT-proBNP)—a marker of disease progression in transthyretin-mediated ...
Seeking Alpha

Alnylam raises 2025 revenue guidance to $3.05B amid robust AMVUTTRA ATTR-CM launch momentum

CEO Yvonne Greenstreet highlighted that "Alnylam's Q3 results announced this morning demonstrate the exceptional progress we are making across all aspects of the business." Greenstreet stated, "Our ...
Mint

Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z

Intellia Therapeutics has temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z, a CRISPR-based therapy for transthyretin amyloidosis with ...
pharmaphorum

CRISPR biotech Intellia plummets as trial paused for safety

Gene-editing specialist Intellia Therapeutics lost more than 45% of its value in pre-market trading today as it revealed phase 3 trials of one of its two priority programmes had been suspended due to ...
Healthline

What to Know About Transthyretin Amyloidosis (ATTR) Genetic Testing

Genetic testing for ATTR can detect transthyretin mutations and offer crucial information about risk, monitoring, and treatment, if needed. Transthyretin amyloidosis (ATTR) is a genetic condition that ...
AOL

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. The study showed that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular ...